TNFRSF17 and Miyoshi myopathy: Ciltacabtagene autoleucel (Cilta-cel, previously known as LCAR-B38M) is a biepitopic CAR-T product targeting BCMA antigen, and has achieved remarkable success in the treatment of relapsed/refractory (r/r) MM patients in China3,8,9 and United States of America (US)10.